Search Within

Nivetha Ganesan

Formats
  1. Meeting Abstract (41)
  2. Journal Article (12)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (53)
  2. Department of Medicine (53)
  3. Hematologic Malignancies, Division of (53)
  4. Lymphoma (53)
  5. Population Sciences Research Program (46)
  6. Hematology-Oncology Fellows (44)

More Groups

People
  1. Steven Horwitz (46)
  2. Alison Moskowitz (43)
  3. Natasha Galasso (35)
  4. Ahmet Dogan (27)
  5. Paola Ghione (27)
  6. Ariela Noy (26)

More People

Years
  1. 2025 (1)
  2. 2024 (12)
  3. 2023 (15)
  4. 2022 (5)
  5. 2021 (9)
  6. 2020 (5)

More Years

Publications
  1. Blood (33)
  2. Hematological Oncology (5)
  3. Journal of Clinical Oncology (5)
  4. Blood Advances (3)
  5. American Journal of Hematology (1)
  6. Cancer Research (1)

More Publications

Publishers
  1. American Society of Hematology (36)
  2. American Society of Clinical Oncology (5)
  3. Wiley Blackwell (5)
  4. American Association for Cancer Research (1)
  5. American Association for the Advancement of Science (1)
  6. Elsevier Science, Inc. (1)

More Publishers

Results (54)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of reduced dose brentuximab vedotin for cutaneous T‐cell lymphomas
    Meeting Abstract

    Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Symptomatic delayed seromas vs incidental findings on MR, and likelihood of BIA-ALCL in women with textured implants
    Meeting Abstract

    Ghione, P.; Sutton, E. J.; Hu, Q.; Galasso, N.; Ganesan, N.; Tyagi, N.; Martinez, D. F.; Dogan, A.; Morris, E. A.; Horwitz, S. M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Multispectral immunofluorescence identifies pS6 as a biomarker of intrinsic resistance to ruxolitinib in patients with relapsed/refractory T-cell lymphomas
    Meeting Abstract

    Ghione, P.; Moskowitz, A.; Kumar, P.; Knezevic, A.; Seshan, V.; Jacobsen, E.; Ruan, J.; Schatz, J.; Noor, S.; Myskowski, P.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • T follicular helper phenotype prendicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma
    Journal Article

    Ghione, P.; Faruque, P.; Mehta-Shah, N.; Seshan, V.; Ozkaya, N.; Bhaskar, S.; Yeung, J.; Spinner, M. A.; Lunning, M.; Inghirami, G.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants
    Journal Article

    Cordeiro, P. G.; Ghione, P.; Ni, A.; Hu, Q.; Ganesan, N.; Galasso, N.; Dogan, A.; Horwitz, S. M.
    Journal of Plastic Reconstructive and Aesthetic Surgery (2020)

    Fulltext@MSK | Save
  • Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E. D.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Hancock, H.; Davey, T.; Obadi, O.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Incidence of delayed seromas and related risk of BIA-ALCL in a cohort of 3521 breast cancer women with textured implants prospectively followed long term
    Meeting Abstract

    Ghione, P.; Cordeiro, P.; Seshan, V.; Galasso, N.; Ganesan, N.; Hu, Q.; Dogan, A.; Horwitz, S. M.
    Blood (2019)

    Fulltext@MSK | Save
  • Risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3,546 women prospectively followed after receiving textured breast implants
    Meeting Abstract

    Ghione, P.; Cordeiro, P. G.; Ni, A.; Hu, Q. Y.; Ganesan, N.; Galasso, N.; Dogan, A.; Horwitz, S. M.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save